Monday Lunch Livestream

with Dr Mary Ann Anderson

5 December 2022

Despite significant advances in the management of patients the optimal use of BH3 mimetics remains to be fully clear.

Dr Mary Ann Anderson will explain the history and main current uses of BH3 mimetics in B cell malignancies while highlighting key areas where these agents can be optimised.